Telogen effluvium: a sequela of COVID‐19.

Dear Editor, Since the emergence of the novel coronavirus SARS-CoV-2, the cause of COVID-19, heavy attention has been paid to its life-threatening pulmonary and cardiovascular manifestations.1 However, cutaneous signs and symptoms of disease have also been described and may significantly impact patients.2 While preliminary characterizations have aptly set expectations for acute disease course, it is imperative to establish similar familiarity with late-course and postinfectious manifestations to guide appropriate treatment and patient education. In the ambulatory dermatology clinic, one such increasingly apparent manifestation has been new onset diffuse hair loss in patients previously infected with SARS-CoV-2, clinically compatible with telogen effluvium (TE). The telogen phase lasts approximately 3 months, after which excessive hair loss ensues.3 Herein, we present 10 patients with concerns of increased hair loss following SARS-CoV-2 infection (Table 1). [Extracted from the article]